Fox Run Management, L.L.C. Intellia Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$23.16 - $32.34 $191,811 - $267,839	8,282 Added 77.0%	19,038 $580,000
Q3 2023 Nov 07, 2023	BUY	$31.62 - $45.78 $340,104 - $492,409	10,756 New	10,756 $340,000
Q1 2023 May 12, 2023	BUY	$33.3 - $44.82 $370,262 - $498,353	11,119 New	11,119 $414,000
Q2 2022 Aug 12, 2022	SELL	$38.49 - $76.21 $176,207 - $348,889	-4,578 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$58.27 - $118.99 $266,760 - $544,736	4,578 New	4,578 $333,000
Q1 2018 Apr 17, 2018	SELL	$19.43 - $34.95 $232,577 - $418,351	-11,970 Closed	0 $0
Q4 2017 Jan 18, 2018	BUY	$17.39 - $31.12 $208,158 - $372,506	11,970	11,970 $230,000

313

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $929M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.